• 1
    Ferguson M, Wilkinson DE, Zhou T. WHO meeting on the standardization of HPV assays and the role of the WHO HPV Laboratory Network in supporting vaccine introduction held on 24-25 January 2008, Geneva, Switzerland. Vaccine 2009; 27: 337347.
  • 2
    Barzon L, Giorgi C, Buonaguro FM, Palù G; Italian Society for Virology. Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention. Infect Agent Cancer 2008; 3: 14.
  • 3
    Saslow D, Solomon D, Lawson HW et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012; 62: 147172.
  • 4
    Bouvard V, Baan R, Straif K et al. A review of human carcinogens – Part B: biological agents. Lancet Oncol 2009; 10: 321322.
  • 5
    Guan P, Howell-Jones R, Li N et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 2012; 131: 23492359.
  • 6
    Eklund C, Zhou T, Dillner J; WHO Human Papillomavirus Laboratory Network. Global proficiency study of human papillomavirus genotyping. J Clin Microbiol 2010; 48: 41474155.
  • 7
    Eklund C, Forslund O, Wallin KL, Zhou T, Dillner J; for theWHO Human Papillomavirus Laboratory Network. Global proficiency study of human papillomavirus genotyping in vaccinology. J Clin Microbiol 2012; 50: 22892298.
  • 8
    de Sanjose S, Quint WG, Alemany L et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11: 10481056.
  • 9
    Geraets D, Alemany L, Guimera N et al. Detection of rare and possibly carcinogeneic human papillomavirus genotypes as single infections in invasive cervical cancer. J Pathol 2012. doi: 10.1002/path.4065. [Epub ahead of print].
  • 10
    Barzon L, Militello V, Lavezzo E et al. Human papillomavirus genotyping by 454 next generation sequencing technology. J Clin Virol 2011; 52: 9397.
  • 11
    WHO. Human papillomavirus laboratory manual, 1st edn. 2009. Available at:
  • 12
    Militello V, Trevisan M, Squarzon L et al. Investigation on the presence of polyomavirus, herpesvirus, and papillomavirus sequences in colorectal neoplasms and their association with cancer. Int J Cancer 2009; 124: 25012503.
  • 13
    Schmitz M, Scheungraber C, Herrmann J et al. Quantitative multiplex PCR assay for the detection of the seven clinically most relevant high-risk HPV types. J Clin Virol 2009; 44: 302307.
  • 14
    Castle PE, Schiffman M, Burk RD et al. Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol Biomarkers Prev 2002; 11: 13941399.
  • 15
    Poljak M, Marin IJ, Seme K, Vince A. Hybrid Capture II HPV test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail. J Clin Virol 2002; 25 (Suppl 3): S89S97.
  • 16
    Castle PE, Solomon D, Wheeler CM, Gravitt PE, Wacholder S, Schiffman M. Human papillomavirus genotype specificity of hybrid capture 2. J Clin Microbiol 2008; 46: 25952604.
  • 17
    Bernard HU, Chan SY, Manos MM et al. Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification restriction fragment length polymorphisms, nucleotide sequences and phylogenetic algorithms. J Infect Dis 1994; 170: 10771085.
  • 18
    de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004; 324: 1727.
  • 19
    Barbieri D, Nocera M, Gallinella G et al. Comparison of HPV sign Genotyping Test with INNO-LiPA HPV Genotyping Extra assay on histologic and cytologic cervical specimens. Diagn Microbiol Infect Dis 2012; 74: 4348.